Treatment of Pathological Gambling With Naltrexone Pharmacotherapy and Brief Intervention
Primary Purpose
Pathological Gambling
Status
Completed
Phase
Phase 4
Locations
Finland
Study Type
Interventional
Intervention
Naltrexone pharmacotherapy
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Pathological Gambling focused on measuring Pathological gambling, Treatment intervention
Eligibility Criteria
Inclusion Criteria:
- pathological gambling (scores 5+ from SOGS-R and DSM-IV criteria)
Exclusion Criteria:
- acute hepatitis
- severe liver or kidney dysfunction
- suicide risk or severe depression or other untreated mental health problem
- participation to other gambling research at the same time
- the use of drugs (especially opiates)
- pregnancy
- prisoners
- retarded and mentally ill patients were also excluded
Sites / Locations
- National Institute for Health and Welfare
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Active Comparator
Arm Label
Placebo pill.
50mg Naltrexone when needed
Arm Description
Outcomes
Primary Outcome Measures
PG-YBOCS.
The investigators will interview PG-YBOCS questionnaire from the participants.
Secondary Outcome Measures
Alcohol use.
The investigators will ask the participants to fill in AUDIT questionnaire.
Quality of life.
The investigators will ask the participants to fill in RAND 36 questionnaire.
Full Information
NCT ID
NCT01528007
First Posted
October 28, 2011
Last Updated
December 4, 2013
Sponsor
Finnish Institute for Health and Welfare
1. Study Identification
Unique Protocol Identification Number
NCT01528007
Brief Title
Treatment of Pathological Gambling With Naltrexone Pharmacotherapy and Brief Intervention
Official Title
Treatment of Pathological Gambling With Naltrexone Pharmacotherapy and Brief Intervention - a Placebo Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
December 2013
Overall Recruitment Status
Completed
Study Start Date
January 2011 (undefined)
Primary Completion Date
September 2013 (Actual)
Study Completion Date
September 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Finnish Institute for Health and Welfare
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The aim of this research is to explore the efficacy of the opiate antagonist, naltrexone as combined with CBT-intervention in the treatment of pathological gambling (PG). The study period is 2011-2014 during which one hundred Pathological Gamblers will be recruited to participate to this placebo-controlled double-blind trial.
Detailed Description
All participants have to be able to read and understand the patient information sheet and sign the informed consent. All participants are free to stop being in the study whenever they wanted. The patients are not paid or reimbursed for participation.
The study periods is 21 weeks during which the participant's have 8 appointments with the researchers. During the meetings research data will be collected and the participant is having Controlled Behavioral Therapy (CBT) consulting from a trained therapist. At the study visits, the subjects are given written instructions for the proper use of naltrexone and advised to take 50 mg naltrexone approximately one hour before gambling or feeling urges to gamble (and to refrain from taking naltrexone at other times). In this study the maximal daily dose is 50mg of naltrexone. The medication is free for the subjects.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pathological Gambling
Keywords
Pathological gambling, Treatment intervention
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
100 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Placebo pill.
Arm Type
Placebo Comparator
Arm Title
50mg Naltrexone when needed
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Naltrexone pharmacotherapy
Intervention Description
Naltrexone 50mg when graving to gamble.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo pill with no active ingredients.
Primary Outcome Measure Information:
Title
PG-YBOCS.
Description
The investigators will interview PG-YBOCS questionnaire from the participants.
Time Frame
Up to 21 weeks.
Secondary Outcome Measure Information:
Title
Alcohol use.
Description
The investigators will ask the participants to fill in AUDIT questionnaire.
Time Frame
Up to 21 weeks.
Title
Quality of life.
Description
The investigators will ask the participants to fill in RAND 36 questionnaire.
Time Frame
Up to 21 weeks.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
pathological gambling (scores 5+ from SOGS-R and DSM-IV criteria)
Exclusion Criteria:
acute hepatitis
severe liver or kidney dysfunction
suicide risk or severe depression or other untreated mental health problem
participation to other gambling research at the same time
the use of drugs (especially opiates)
pregnancy
prisoners
retarded and mentally ill patients were also excluded
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hannu Alho, Professor
Organizational Affiliation
Finnish Institute for Health and Welfare
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Tuuli Lahti, Adjunct Professor
Organizational Affiliation
Finnish Institute for Health and Welfare
Official's Role
Study Director
Facility Information:
Facility Name
National Institute for Health and Welfare
City
Helsinki
State/Province
Uusimaa
ZIP/Postal Code
00530
Country
Finland
12. IPD Sharing Statement
Citations:
PubMed Identifier
36130734
Citation
Dowling N, Merkouris S, Lubman D, Thomas S, Bowden-Jones H, Cowlishaw S. Pharmacological interventions for the treatment of disordered and problem gambling. Cochrane Database Syst Rev. 2022 Sep 22;9(9):CD008936. doi: 10.1002/14651858.CD008936.pub2.
Results Reference
derived
PubMed Identifier
26339899
Citation
Kovanen L, Basnet S, Castren S, Pankakoski M, Saarikoski ST, Partonen T, Alho H, Lahti T. A Randomised, Double-Blind, Placebo-Controlled Trial of As-Needed Naltrexone in the Treatment of Pathological Gambling. Eur Addict Res. 2016;22(2):70-9. doi: 10.1159/000435876. Epub 2015 Sep 5.
Results Reference
derived
Learn more about this trial
Treatment of Pathological Gambling With Naltrexone Pharmacotherapy and Brief Intervention
We'll reach out to this number within 24 hrs